Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Up 171.5% in May
Innate Pharma’s Sponsored ADR (NASDAQ:IPHA) saw short interest rise 171.5% in May, reaching 245,729 shares as of May 15 versus 90,515 on April 30, according to the article. Short interest equals 0.4% of shares; days to cover is 1.0. The stock traded at $1.83 midday. Analysts cited mixed ratings and targets ($5.00 average).
How this was made
The 30-second read
Why it matters
The primary tradable element is the May short-interest jump, which can influence borrow demand, intraday volatility, and how traders interpret risk ahead of the next fundamental catalyst (earnings/trial updates).
Market read
Positioning shifted materially in May (short interest +171.5%), which can drive short-term volatility even without new clinical/financial results.
What to watch
The article cites analyst rating changes and price targets, but does not link them to a specific new company event; fundamentals may be unchanged despite positioning shifts.
Background
The piece is a short-interest/positioning update for Innate Pharma’s NASDAQ-listed sponsored ADR, plus a recap of recent analyst coverage and a brief trading snapshot.
Ticker impact
Innate Pharma’s short interest jumped 171.5% in May, with days-to-cover at 1.0, signaling a sharp change in positioning.
Near-term: choppy/volatile trading bias; direction uncertain without follow-on news.
The datapoint is time-specific (May 15 short interest) and positioning-related, yet it’s not tied to new trial/earnings outcomes in the article.
Market effects
For small-cap clinical biotech, short-interest spikes can amplify risk-off moves and widen spreads around upcoming catalysts.
Limited—primarily impacts US-listed ADR trading liquidity and sentiment.
Low—no cross-border deal/regulatory event described.
Counterpoint
A large % increase can still be small in absolute terms for low-float names; low days-to-cover (1.0) may reduce squeeze intensity.
Key entities
- companyInnate Pharma S.A. Sponsored ADR
Subject of the short-interest change and recent analyst coverage discussed in the article.
- institutionMillennium Management LLC
Purchased a new stake per the article’s institutional activity summary.
- institutionJane Street Group LLC
Purchased a new stake per the article’s institutional activity summary.
